Constantinou A, Stoner G D, Mehta R, Rao K, Runyan C, Moon R
Department of Surgical Oncology, College of Medicine, University of Illinois at Chicago 60612, USA.
Nutr Cancer. 1995;23(2):121-30. doi: 10.1080/01635589509514368.
Ellagic acid and 12 related agents have been tested for their ability to inhibit the activities of human DNA topoisomerase (topo) I and II. Using specific in vitro assays, we found ellagic acid and flavellagic acid to be potent inhibitors of the catalytic activities of the two topoisomerases. The minimum concentration required to inhibit > or = 50% of catalytic activity (IC50) of ellagic acid was determined at 0.6 and 0.7 micrograms/ml for topo I and topo II, respectively. Flavellagic acid's IC50 was determined at 3.0 and 3.6 micrograms/ml for topo I and topo II, respectively. Unlike topoisomerase poisons, these two plant phenols did not trap the enzyme-DNA reaction intermediate, known as the cleavable complex. In contrast, ellagic acid prevented other topo I and topo II poisons from stabilizing the cleavable complex, suggesting that the mode of its action is that of an antagonist. Structure-activity studies identified the 3,3'-hydroxyl groups and the lactone groups as the most essential elements for the topoisomerase inhibitory actions of plant phenols. On the basis of these findings and other properties of ellagic acid, a mechanistic model for the documented anticarcinogenic effects of the agent is proposed.
对鞣花酸及12种相关试剂抑制人类DNA拓扑异构酶(topo)I和II活性的能力进行了测试。通过特定的体外试验,我们发现鞣花酸和黄酮鞣花酸是这两种拓扑异构酶催化活性的有效抑制剂。对于拓扑异构酶I和拓扑异构酶II,抑制>或 = 50%催化活性(IC50)所需的最低浓度,鞣花酸分别为0.6和0.7微克/毫升。黄酮鞣花酸对拓扑异构酶I和拓扑异构酶II的IC50分别为3.0和3.6微克/毫升。与拓扑异构酶毒物不同,这两种植物酚类不会捕获酶-DNA反应中间体,即所谓的可裂解复合物。相反,鞣花酸可阻止其他拓扑异构酶I和拓扑异构酶II毒物稳定可裂解复合物,这表明其作用模式是拮抗剂。结构-活性研究确定3,3'-羟基和内酯基团是植物酚类对拓扑异构酶抑制作用的最关键要素。基于这些发现以及鞣花酸的其他特性,提出了该试剂已记录的抗癌作用的机制模型。